TX-MARY-KAY-INC
Mary Kay Inc., a global advocate for corporate social responsibility, today released a report detailing progress on Enriching Lives Today for a Sustainable Tomorrow (ELTFAST), the brand’s global sustainability program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005001/en/
Enriching Lives Today for a Sustainable Tomorrow extends Mary Kay's vision to 2030 and beyond. (Credit: Mary Kay Inc.)
“We’re proud of the progress we’ve made on our sustainability journey so far, and we are inspired to see how our actions today will address global challenges for future generations,” said Deborah Gibbins, Chief Operating Officer at Mary Kay Inc. “Mary Kay has operations in nearly 35 countries—we consider that an accomplishment and a responsibility. Enriching Lives Today for a Sustainable Tomorrow is our roadmap for supporting our business strategy, reducing our environmental impact, and supporting communities where we operate.”
Enriching Lives Today for a Sustainable Tomorrow extends Mary Kay’s vision to 2030 and beyond. It builds a picture of what good “looks like” for Mary Kay, Independent Beauty Consultants, customers and—most importantly—the planet. Enriching Lives Today for a Sustainable Tomorrow was developed with Mary Kay’s key stakeholders and is aligned with the United Nations’ Sustainable Development Goals, making Mary Kay a key part of a global coalition to ensure a better future.
The 2020 – 2022 full report can be viewed here. An executive summary of the report is available here.
Since the launch of ELTFAST in 2020, Mary Kay has made significant progress toward its goals despite the many challenges presented by the COVID-19 epidemic. The 2022 report details its efforts since 2020—the beginning of its Decade of Action—and serves as a reaffirmation of the company’s drive to deliver sustainable change.
Business Excellence
- Focusing on nurturing its company culture, Mary Kay garnered 13 employer / great place to work awards and was ranked #8 on list of “The Companies Employees Don’t Want to Leave,” published by Resume.io.
- Released gender diversity data in leadership: executive team is 54% female, managers and above are 59% female, with 62% of the total workforce being female.
- In 2021, scored 75% employee engagement, a 6% increase over the 2019 full engagement survey (This is 10% over the global average for employee engagement).
- 38 company awards in business excellence, social impact, and sustainability.
-
Deloitte named Mary Kay Inc. one of the 2022 U.S. Best Managed Companies.
Product Stewardship
- Achieved Forest Stewardship Council (FSC) certification (U.S.A only). The FSC certification ensures products come from responsibly managed forests providing environmental, social and economic benefits.
- 12% of our indirect suppliers are women, minority or veteran-owned (U.S.A. only).
- Achieved palm oil–88% certified and palm kernel–72% certified.
- Held inaugural Sustainability-Focused Supplier Summit at global headquarters.
- Named 2022 Silver Champion for Supplier Diversity & Inclusion.
-
Nominated and approved member of the steering committee for SPICE (Sustainable Packaging Initiative for CosmEtics).
Responsible Manufacturing
- Supported The Arbor Day Foundation on three global reforestation projects in Brazil, Madagascar, and the United States.
- Continued additional water usage analysis with plans to install new water flow meters.
- Supported The Nature Conservancy’s Global Reefs program through 12 unique impact programs.
- Joined the UN Global Compact’s Ocean Stewardship Coalition.
- Richard R. Rogers Manufacturing/R&D facility (R3), announced it passed its OSHA VPP Star Re-Certification with zero findings and recommendations.
- Received OSHA Star Re-Certification Credentials.
Women’s Empowerment
- Published “Piloting SDG Localization at the Village Level: A Women-focused Poverty Reduction and Sustainable Development Project in Yunnan Province, China.” Impact Report (Phase 1: 2017-2021).
- Completed The Women’s Empowerment Principles Gender Gap Analysis Tool as part of our participation in the UN Global Compact Target Gender Equality Accelerator.
- Advanced women’s leadership in the fishing industry in Mexico through eight projects implemented by The Nature Conservancy.
- Powered the global launch of a free Entrepreneurship Program in six languages, developed by International Trade Centre SheTrades Initiative.
- Awarded 14 STEAM grants to young women around the world pursuing dreams in STEAM-related industries.
- Joined the UN Global Compact Target Gender Equality Program to deepen implementation of the Women’s Empowerment Principles.
- Submitted survey on the implementation of commitments across the Generation Equality Action Coalitions; findings reflected in UN Women’s Generation Equality Accountability Report 2022.
Social Impact
- Since 2008, Pink Changing Lives has impacted more than six million women and their families by partnering with over 3,250 organizations and donating over $17 million. In 2022, the cause empowerment program supported over 20 NGOs around the world.
- Mary Kay and the Mary Kay Ash Foundation grants supported the development and launch of a “GBV Guidance for Development Programs” and its rollout in 10 countries of intervention as well as the establishment of a Community of Practice convening 240 members across 16 countries to date.
- Mary Kay and the Mary Kay Ash Foundation grants helped the UN Trust Fund change the lives of 54,822 women and girl survivors of violence through 157 GBV projects in 68 countries across five regions including women and girls living with disabilities, internally displaced or refugee women and girls, and Indigenous women and girls.
- Donated more than $1.3 million to global organizations helping to enrich women’s lives.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
